Dassault Systèmes in talks to buy drug trial software company for about $2bn
Potential purchase of ArisGlobal from Swedish buyout group would boost French conglomerate’s push into life sciences
Record details
Published: 16 July 2026
Source: Financial Times Technology (headlines)
Category: News
Topics: Healthcare
Retrieved: 17 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
AI and a brain implant restored a paralysed man’s movement and touch
The Next Web AI · 16 July 2026
STAT+: GOP blocks effort to end Medicare test of AI prior authorization
STAT News (health AI, headlines) · 16 July 2026
Harvard cancer researchers earn retraction for image duplication
Retraction Watch · 16 July 2026
Paralysed man regains hand function through novel brain technology
Financial Times Technology (headlines) · 16 July 2026
We Need Political Philosophy for Mental Health Chatbots
Tech Policy Press · 16 July 2026
Coalition Urges Policymakers To Reject No Surprises Act Enforcement Bill
Above the Law (legal tech) · 16 July 2026
How to cite this record
ethics.ai (16 July 2026), “Dassault Systèmes in talks to buy drug trial software company for about $2bn,” evidence record 11122, https://ethics.ai/record/11122 (originally published by Financial Times Technology (headlines)).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.